CBP 501

Drug Profile

CBP 501

Alternative Names: CBP-501; Cdc25C phosphatase (211-221)

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CanBas
  • Class Antineoplastics; Peptides
  • Mechanism of Action 14-3-3 protein inhibitors; Calmodulin antagonists; Checkpoint kinase 1 inhibitors; Checkpoint kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mesothelioma; Non-small cell lung cancer
  • Phase I Solid tumours
  • Discontinued Ovarian cancer

Most Recent Events

  • 20 Sep 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT03113188)
  • 04 Jul 2017 CBP 501 is still in phase II development for Mesothelioma and Non-small-cell lung cancer (CanBas pipeline, July 2017)
  • 03 Jul 2017 Phase II trial of CBF 501 fails to meet its primary endpoint of progression free survival in patients with non-small-cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top